Gastroenterology Report

Papers
(The H4-Index of Gastroenterology Report is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Gastrointestinal cancers in China, the USA, and Europe94
BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy59
Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance57
Role of gut microbiota in functional constipation54
Phage-mediated horizontal gene transfer and its implications for the human gut microbiome47
Tea polyphenol EGCG inhibited colorectal-cancer-cell proliferation and migration via downregulation of STAT3 38
Microbiome therapeutics: exploring the present scenario and challenges34
Metabolic alterations and vulnerabilities in hepatocellular carcinoma30
Radiomics based on artificial intelligence in liver diseases: where are we?29
Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells25
The influence of mitochondrial-directed regulation of Wnt signaling on tumorigenesis23
lncRNA-PACER upregulates COX-2 and PGE2 through the NF-κB pathway to promote the proliferation and invasion of colorectal-cancer cells22
Clinical characteristics and survival analysis of colorectal cancer in China: a retrospective cohort study with 13,328 patients from southern China21
Genetic and epigenetic dependencies in colorectal cancer development20
Cronkhite–Canada syndrome: from clinical features to treatment19
Sodium butyrate protects against lipopolysaccharide-induced liver injury partially via the GPR43/ β-arrestin-2/NF-κB network18
Influence of microbiota on immunity and immunotherapy for gastric and esophageal cancers17
Convergent pathways of the gut microbiota–brain axis and neurodegenerative disorders17
Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma17
0.037652969360352